Table 2A:

Clinicopathological metrics and PDO drug screening results for patients treated with modified FOLFIRINOX (mFFX) in NAT setting.

PDO ID	Timing of Tissue Collection for PDOa	Chemotherapy Tumor Before Surgical Resection (doses)	NAT Radiation (doses)	CA 19–9 Percent Decrease (%)b	Radiographic Tumor Size Percent Decrease (%)c	Surgical Pathology Tumor Cellularity (%)d	Pathology NAT Responsee	RFS (months)f	Biobank Predicted Response	PDO Sensitivity/Resistance AUC
hT297	post-NAT	mFFX (8)	0	95	0	86	3	3.7mon	5-FU = R Oxaliplatin = R SN-38 = R	5FU:1.0 Oxali: 1.4 SN38: 1.09 AUC Sum: 3.49
hT282	post-NAT	mFFX (9)	0			73	2	5.2 mon	5-FU = R Oxaliplatin = S SN-38 = R	5FU: 0.99 Oxali: 0.78 SN38: 0.78 AUC Sum: 2.55
hT241	post-NAT	mFFX (6) -> GnP (6)	3000cGY	88	8	75	2	7.8 mon	5-FU = A Oxaliplatin = S SN-38 = R	5FU: 0.83 Oxali: 0.70 SN38: 0.66 AUC Sum: 2.19
hF215	pre-NAT	mFFX	0						5-FU = S Oxaliplatin = A SN-38 = R	5FU:0.62 Oxali: 0.89 SN38: 0.64 AUC Sum: 2.15
hF154	pre-NAT	mFFX	0						5-FU = S Oxaliplatin = R SN-38 =S	5FU:0.63 Oxali: 0.94 SN38: 0.55 AUC Sum: 2.12
hT277	post-NAT	mFFX (9)	0	88	43	38	2	14.3 mon	5-FU = S Oxaliplatin = S SN-38 = A	5FU:0.6 Oxali: 0.73 SN38: 0.58 AUC Sum: 1.91

Abbreviations: PDO, patient-derived organoids; GnP, gemcitabine/abraxane; mFFX, modified FOFIRINOX; NAT, neoadjuvant; RFS, recurrence free survival; R, resistant; S, sensitive; A, average.

^aPre-NAT, biopsy specimen obtained prior to initiation of NAT chemotherapy; post-NAT, surgical specimen obtained after NAT completion at the time of primary tumor resection.

^bThe change in CA 19–9 levels before and after chemotherapy divided by the starting value and multiplied by 100.

^cThe change in the tumor size determined by computed tomography (CT) pancreas protocol before and after chemotherapy divided by the starting value and multiplied by 100.

^dSurgical Pathology Tumor Cellularity (%) score was calculated as the number of histology slides with viable adenocarcinoma divided by the total number of slides sampled from the resected tumor.

^eAccording CAP protocol³

^fRecurrence Free Survival (RFS) was calculated from the date of surgery until the date of recurrence.